All Comments by John Trojanowski

  1. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study.
  2. A Blood Test for AD?
  3. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
  4. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease.
  5. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS.
  6. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
  7. Detecting antigens by quantitative immuno-PCR.
  8. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.
  9. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse.
  10. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
  11. Oligomeric alpha-synuclein inhibits tubulin polymerization.
  12. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
  13. Alzheimer's researchers open the doors to data sharing.
  14. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
  15. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.